These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25882803)

  • 1. Effective strategies for managing new Pseudomonas cultures in adults with cystic fibrosis.
    Ali H; Orchard C; Mariveles M; Scott S; Alshafi K; Bilton D; Simmonds N
    Eur Respir J; 2015 Sep; 46(3):862-5. PubMed ID: 25882803
    [No Abstract]   [Full Text] [Related]  

  • 2. Post-antibiotic effect of colistin, alone and in combination with amikacin, on Pseudomonas aeruginosa strains isolated from cystic fibrosis patients.
    Bozkurt-Güzel C; Gerçeker AA
    J Antibiot (Tokyo); 2012 Feb; 65(2):83-6. PubMed ID: 22126897
    [No Abstract]   [Full Text] [Related]  

  • 3. Reclassification of CLSI criteria for ciprofloxacin and levofloxacin susceptibility against Pseudomonas aeruginosa: Implications for patients with cystic fibrosis (CF).
    Millar BC; Malnarcic CM; McCaughan J; Moore JE
    Clin Respir J; 2020 Jan; 14(1):64-68. PubMed ID: 31663261
    [No Abstract]   [Full Text] [Related]  

  • 4. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.
    Herrmann G; Yang L; Wu H; Song Z; Wang H; Høiby N; Ulrich M; Molin S; Riethmüller J; Döring G
    J Infect Dis; 2010 Nov; 202(10):1585-92. PubMed ID: 20942647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
    Hansen CR; Pressler T; Høiby N
    J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of antibiotic susceptibility patterns in Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) with invasive Pseudomonas aeruginosa from non-CF patients.
    Rao P; McCaughan J; McCalmont M; Goldsmith CE; Hall V; Millar BC; McCann MA; Downey DG; Rendall JC; Elborn JS; Moore JE
    J Cyst Fibros; 2012 Jul; 11(4):349-52. PubMed ID: 22325689
    [No Abstract]   [Full Text] [Related]  

  • 7. Pulmonary exacerbations in cystic fibrosis: it's time to be explicit!
    Marshall BC
    Am J Respir Crit Care Med; 2004 Apr; 169(7):781-2. PubMed ID: 15044219
    [No Abstract]   [Full Text] [Related]  

  • 8. In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany.
    Schülin T
    J Antimicrob Chemother; 2002 Feb; 49(2):403-6. PubMed ID: 11815589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical use of colistin in patients with cystic fibrosis.
    Beringer P
    Curr Opin Pulm Med; 2001 Nov; 7(6):434-40. PubMed ID: 11706322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outpatient treatment of Pseudomonas aeruginosa bronchial colonization with long-term inhaled colistin, tobramycin, or both in adults without cystic fibrosis.
    Berlana D; Llop JM; Manresa F; Jódar R
    Pharmacotherapy; 2011 Feb; 31(2):146-57. PubMed ID: 21275493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis.
    Guillot E; Sermet I; Ferroni A; Chhun S; Pons G; Zahar JR; Jullien V
    Pharmacotherapy; 2010 Dec; 30(12):1252-8. PubMed ID: 21114393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.
    Tiddens HA; De Boeck K; Clancy JP; Fayon M; H G M A; Bresnik M; Derchak A; Lewis SA; Oermann CM;
    J Cyst Fibros; 2015 Jan; 14(1):111-9. PubMed ID: 25091537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fosfomycin for Pseudomonas-related exacerbations of cystic fibrosis.
    Faruqi S; McCreanor J; Moon T; Meigh R; Morice AH
    Int J Antimicrob Agents; 2008 Nov; 32(5):461-3. PubMed ID: 18703318
    [No Abstract]   [Full Text] [Related]  

  • 14. Resistance to tobramycin and colistin in isolates of Pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment.
    Valenza G; Radike K; Schoen C; Horn S; Oesterlein A; Frosch M; Abele-Horn M; Hebestreit H
    Scand J Infect Dis; 2010 Dec; 42(11-12):885-9. PubMed ID: 20735333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis.
    Pastor M; Moreno-Sastre M; Esquisabel A; Sans E; Viñas M; Bachiller D; Asensio VJ; Pozo AD; Gainza E; Pedraz JL
    Int J Pharm; 2014 Dec; 477(1-2):485-94. PubMed ID: 25445528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre.
    Manno G; Cruciani M; Romano L; Scapolan S; Mentasti M; Lorini R; Minicucci L
    Int J Antimicrob Agents; 2005 Mar; 25(3):193-7. PubMed ID: 15737511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.
    Stass H; Delesen H; Nagelschmitz J; Staab D
    J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):106-15. PubMed ID: 25050456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of a Reduction in Susceptibility Testing for
    Ponce MC; Svendsen E; Steed L; Flume PA
    Am J Respir Crit Care Med; 2020 Jan; 201(1):114-116. PubMed ID: 31469583
    [No Abstract]   [Full Text] [Related]  

  • 19. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols.
    Taccetti G; Bianchini E; Cariani L; Buzzetti R; Costantini D; Trevisan F; Zavataro L; Campana S;
    Thorax; 2012 Oct; 67(10):853-9. PubMed ID: 22379071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct comparison of in vitro susceptibility of wildtype clinical Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) to TOBI and BRAMITOB (tobramycin inhalation solutions).
    Moore JE; Maeda Y; Goldsmith CE; Rendall JC; Elborn JS
    J Cyst Fibros; 2010 May; 9(3):237-8. PubMed ID: 20378421
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.